Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects

NCT ID: NCT01084343

Last Updated: 2012-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2010-09-30

Brief Summary

This study is designed to investigate the safety and efficacy of a newly developed vaccine against HIV-1 in female healthy subjects. Safety will be assessed by local and systemic adverse reactions, investigations of blood and urine, and physical exam including vital sign measurements. Efficacy will be assessed in blood, and in vaginal and rectal mucosal samples.

Detailed Description

The current treatment of HIV is aimed at delaying the disease process after the body has been infected with the virus. HIV treatment does not prevent the spreading of the virus to uninfected people. Prevention of HIV infection could be realized by a vaccine. An effective vaccine could slow down the world wide epidemic. None of the potential vaccines investigated in the past 20 years could provide protection to HIV. All these vaccines were aimed at stimulating an immune reaction in the blood. A new theory has been raised that protection against HIV should take place at the site where the virus in most cases enters the body after sexual contacts, in the vagina and rectum. Mymetics Corporation, sponsor of this clinical trial, has developed a new vaccine, based on the so-called virosome technique. This vaccine should be able to induce a local immune reaction in the mucosa of vagina and rectum. Investigations in laboratory animals showed that the newly developed vaccine was safe and well tolerated and a local immune reaction in the mucosa could be established. The next step is to investigate if the concept of mucosal immunity does also apply in the human being. Therefore this trial is being designed to investigate if the newly developed vaccine is also safe and well tolerated in healthy subjects. In addition, it will be investigated if the vaccine can induce an immune response in the mucosa of vagina and rectum. The vaccine will be investigated for the first time in man. The vaccine consists of a very small part of the HIV 1 virus, coupled to a carrier, the virosome. The vaccine also contains two proteins of the influenza virus. These are needed for stability of the vaccine and activation of the immune system in general. There will be two groups of 12 healthy female subjects. In total 24 subjects will participate in this study. The first group will be vaccinated with a low dose of the vaccine (10 microgram of peptide). If the vaccine is assessed as safe during the safety reviews, the second group will be vaccinated with a high dose of vaccine (50 microgram of peptide). Safety and tolerability of the high dose will also be assessed during two safety reviews. Each subject will be vaccinated on four occasions, separated by eight weeks. The first two vaccinations will be given in the muscles and the third and fourth vaccination will be given in the nose in order to enhance the immune response in the mucosa. In both groups, eight subjects will be vaccinated with the real vaccine and four subjects will be vaccinated with the carrier only (placebo). Nor the investigator neither the subject will know which vaccination they receive. It will be a so-called double-blinded study. Safety and tolerability will be assessed by the local and systemic adverse reactions. In addition, blood and urine will be investigated and subjects will have a physical examination including vital signs measurements. At home, subjects will complete a diary card for the registration of local and systemic adverse events. The immune response in blood will be measured. For the investigation of the mucosal immune response, a smear from the mucosa of vagina and rectum will be taken and investigated at four visits. This will be performed with special sponges and it is a painless procedure. Total duration of the study for each subject will be 32-34 weeks. HIV infection due to this vaccination is not possible.

Conditions

HIV-1

Keywords

vaccination; prophylaxis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Panel 1

Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).

Group Type: ACTIVE_COMPARATOR

MYM-V101

Intervention Type: BIOLOGICAL

• Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.
• Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.

Panel 2

Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).

Group Type: ACTIVE_COMPARATOR

MYM-V101

Intervention Type: BIOLOGICAL

• Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.
• Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.

Interventions

MYM-V101

• Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.
• Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.

Intervention Type: BIOLOGICAL

Other Intervention Names

MYM-V101.1: low dose intramuscular; MYM-V101.2: high dose intramuscular; MYM-V101.3: high dose intranasal; MYM-V101.4: low dose intranasal

Eligibility Criteria

Inclusion Criteria

1. Female, aged between 18 and 45 years, extremes included

2. Having regular menstrual cycles (24 to 30 days). Women that got sterilized by bilateral tubal ligation are allowed, as long as they have regular cycles

3. Non-smoking or smoking (no more than 10 cigarettes or 2 cigars or 2 pipes per day, for at least 3 months prior to selection)

4. Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, extremes included. BMI is calculated as the weight (in kg) divided by the square of height (in m)

5. Informed Consent Form (ICF) signed voluntarily before first trial-related activity

6. Able to comply with all protocol requirements

7. Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, a gynecological examination, medical history, electrocardiogram, vital signs and the results of blood biochemistry and hematology tests and a urinalysis carried out at screening

8. If the subject is of childbearing potential, agrees to use adequate contraception (oral contraceptives or double barrier method, as described in section 5.2.4, point 7 of the protocol) and not become pregnant for the duration of the study.

Exclusion Criteria

1. Male

2. Female subject without regular menstrual cycle (24-30 days)

3. History of total hysterectomy

4. Female subject of childbearing potential without use of effective birth control method(s), or not willing to continue practicing these birth control method(s) for the duration of the trial

5. Spermicides or other chemicals as used in contraceptive barrier methods (i.e., a male or female condom, diaphragm, cervical cap or intra-uterine device);

6. A positive pregnancy test or breast feeding at screening

7. A positive HIV-1 or HIV-2 test at trial screening

8. Having vaginitis as observed by local inspection and vaginal swab

9. Recurrent vaginal infections or sexually transmitted diseases within one year prior to vaccination

10. A positive test for Hepatitis A (confirmed by hepatitis A antibody IgM), hepatitis B (confirmed by hepatitis B surface antigen), or hepatitis C (confirmed by hepatitis C virus antibody) infection at trial screening

11. History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drugs which in the investigator's opinion would compromise subject safety or compliance with trial procedures

12. Currently active or underlying diabetes, gastrointestinal, cardiovascular, neurological, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, auto-immune disease(s), inheritable immune deficiency(s), infectious disease(s), nasal disorders (i.e. rhinitis, chronic nose bleeds, chronic sinusitis, polyps, chronic cold sores), dental or mouth infections, or rectal problems (fistals, hemorrhoids)

13. History of allergic disease (i.e. egg, milk, dairy products) or reaction likely to be exacerbated by any component of the vaccine to be administered in this trial, and severe allergic disease(s)

14. Contraindication to i.m. injections, history of bleeding disorder or use of anticoagulant therapy within 4 weeks prior to the first study vaccination

15. Having received any of the following substances:

• Nasal or inhalation corticosteroids within 2 weeks prior to first vaccination
• Vaginal and/or rectal treatment within 3 days prior to first mucosal sampling
• HIV vaccine in a prior clinical trial
• Immunosuppressive medications within 6 months prior to first vaccination
• Blood products within 120 days prior to the first vaccination
• Immunoglobulin within 60 days prior to the first vaccination
• Any investigational or non-registered drug or vaccine within 30 days preceding the first vaccination
• Any planned vaccination during the study period and safety follow-up
• Allergy treatment with antigen injections, within 14 days prior to the first study vaccination
• Current anti-tuberculosis preventive therapy or treatment

16. Serious adverse reactions to vaccines such as, but not limited to, anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain or a history of anaphylactic reactions

17. Donation of blood or plasma within the 30 days preceding the first vaccination

18. Acute disease at the time of enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Kinesis Pharma B.V.

INDUSTRY

Sponsor Role: collaborator

CEVAC

UNKNOWN

Sponsor Role: collaborator

M.A.R.C.O.

UNKNOWN

Sponsor Role: collaborator

Mouton's Safety Consultancy

UNKNOWN

Sponsor Role: collaborator

Pharmafour

UNKNOWN

Sponsor Role: collaborator

Pevion

UNKNOWN

Sponsor Role: collaborator

Chimera

UNKNOWN

Sponsor Role: collaborator

Institut Cochin

OTHER

Sponsor Role: collaborator

San Raffaele University Hospital, Italy

OTHER

Sponsor Role: collaborator

INSERM UMR 721

UNKNOWN

Sponsor Role: collaborator

Mymetics Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Mymetics Corporation

Principal Investigators

Geert Leroux-Roels, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

CEVAC, University of Ghent, Belgium

Sylvain Fleury, PhD

Role: STUDY_CHAIR

Mymetics Corporation

Locations

CEVAC

Ghent, , Belgium

Countries

Belgium

References

Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, Adler M, Amacker M, Lopalco L, Bomsel M, Chalifour A, Fleury S. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One. 2013;8(2):e55438. doi: 10.1371/journal.pone.0055438. Epub 2013 Feb 20.

Reference Type: DERIVED

PMID: 23437055 (View on PubMed)

Related Links

http://www.mymetics.com

Sponsor of the trial

http://www.cevac.be

Clinical site of the trial

Other Identifiers

2008-007306-10

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MYM-V101-CT08-101

Identifier Type: -

Identifier Source: org_study_id